Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Surgical outcomes of neoadjuvant durvalumab and chemotherapy in UTUC

Morgan Roupret • 14 Feb 2025
GU Cancers 2025
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma Antibodies Carboplatin Checkpoint Inhibitors Cisplatin Durvalumab Gemcitabine

Morgan Roupret, MD, PhD, Sorbonne University, Paris, France, discusses a Phase II trial (NCT04617756) of neoadjuvant durvalumab with cisplatin- or carboplatin-based chemotherapy in patients with high-risk, non-metastatic upper tract urothelial carcinoma (UTUC). The combination was well tolerated without added surgical risk, and a majority of patients subsequently received robotic radical cystectomy successfully. A Phase III iNDUCT-3 trial will further investigate this approach. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Morgan Roupret

Why does the EAU stand out from other oncology conferences?
1:25
Why does the EAU stand out from other oncology conferences?
Morgan Roupret • 25 Mar 2017
Preventing cystectomy in patients with advanced or complicated bladder cancer
0:54
Preventing cystectomy in patients with advanced or complicated bladder cancer
Morgan Roupret • 25 Mar 2017
Managing side effects in treatment of bladder cancer
0:52
Managing side effects in treatment of bladder cancer
Morgan Roupret • 25 Mar 2017
How can we optimize contemporary bladder cancer care?
1:34
How can we optimize contemporary bladder cancer care?
Morgan Roupret • 26 Mar 2017

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals